Search results
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails -...
Benzinga· 3 days agoPfizer's PFE phase III study of investigational gene therapy, fordadistrogene movaparvovec, for...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks· 5 days agoFree Report) announced that a phase III study on its mini-dystrophin gene therapy fordadistrogene movaparvovec for treating Duchenne muscular dystrophy (“DMD”) failed to meet the primary endpoint ...
Athlete of the Year nominee: Erickson’s athleticism served him well at the Class B level in all...
York News-Times· 5 days agoNOTE: This is the eighth of 10 installments recognizing each of the five finalists for the York...